Study to evaluate the effects of fampridine in patients with multiple sclerosis and eye movement abnormality
What it found
The main measure showed a statistically significant benefit.
“Fampridine significantly reduced both PV-VDI (-17.4%, 95% CI: -22.4%, -12.1%; P < 0.0001) and FPA-VDI (-12.5%, 95% CI: -18.9%, -5.5%; P < 0.01).”Read by software from the paper's abstract
change of peak velocity versional dysconjugacy index (PV-VDI) and first-pass amplitude VDI (FPA-VDI)
mean change difference (fampridine vs placebo) in PV-VDI -17.4% (95% CI -22.4%–-12.1%)
p = < 0.0001 (PV-VDI); P < 0.01 (FPA-VDI)
Read by software from the paper's abstract
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
Primary endpoints
Other measures (1)
Secondary endpoints
Who could take part
MS (type not specified)
Inclusion: 1. Male and female patients 18 years or more of age; Exclusion: 1. Subject is a pregnant female (as determined by a urine pregnancy test), a lactating female, or a female of child-bearing potential, not sterilized and not using one of the following methods of birth control: oral or injectable contraceptive agent, implantable contraceptive device, or barrier method;
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the effects of fampridine on eye movements in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)
Papers
Results
Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.CNS Neurosci Ther · 2019
Fampridine significantly reduced both PV-VDI (-17.4%, 95% CI: -22.4%, -12.1%; P < 0.0001) and FPA-VDI (-12.5%, 95% CI: -18.9%, -5.5%; P < 0.01).
Read by software from the paper's abstract
Loading reviews and guidelines…
Related trials
- AmpPT
Phase 3 · Recruiting
Still running
- RESTORE
Phase 3 · Stopped early
Stopped: not working
- New strategies in neurological diseases
Phase 4 · Ongoing
Still running
- MUST
Not a drug-phase study · Completed
Result in a paper, not read yet
- FAMILY
Completed
Result in a paper, not read yet
- Fampridine Study in Activities of Daily Living
Phase 4 · Completed
No result found
History
Started
Jan 2015
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error